LIVE WEBINAR

 

Risks & Benefits of GLP-1 Therapy in Older Adults

     

OVERVIEW

ADA Member Exclusive Webinar—Join fellow American Diabetes Association® (ADA) professional members for an exclusive, live one-hour webinar featuring an expert panel discussion on the use of GLP‑1 receptor agonists in older adults with type 2 diabetes. This session will examine the clinical benefits and risks of GLP‑1 therapies for individuals with type 2 diabetes and obesity, with a focused look at considerations unique to aging populations—including frailty, polypharmacy, renal function, and other factors that influence therapeutic decision-making.

Participants will gain practical guidance on applying current evidence and guidelines to support personalized treatment approaches for older adults. The discussion will also address gaps in existing data and outline strategies to optimize safety, tolerability, and adherence when prescribing GLP‑1 medicines in this population.

Note: This webinar will be live-only – no recording will be available.

LEARNING OBJECTIVES

  • Define the risks and benefits of GLP‑1 medicines in people with type 2 diabetes and obesity
  • Highlight unique risks and clinical scenarios relevant to older adults
  • Identify gaps in current data and outline strategies for using GLP‑1 medicines in elderly populations

BENEFITS

1 CE Credit

DATE & TIME

February 24, 2026 from 5:00 PM to 6:00 PM ET

EXPIRATION DATE

August 24, 2026

FACULTY 

Daniel Drucker, MD
Senior Scientist, Lunenfeld Tanenbaum Research Institute
LTRI, Sinai Health University of Toronto

FACULTY 

Nuzhat Chalisa, MD
Endocrinologist
Morris Hospital Endocrinology Specialists  

Android App Download IOS App Download Powered By